Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Note that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease ...

The Washington Post says it has obtained documents that detail the five-year experiment involving state Medicaid programs and Medicare Part D plans. Plus: CMS has bumped up Medicare payments for ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock gain as Trump administration to trial Medicare, Medicaid coverage for ...

The Trump administration outlines a plan to cover weight-loss drugs under Medicare and Medicaid, allowing certain state ...